Evidation Announces Leadership Change and New Partnership with American Heart Association

Evidation, a prominent real-world health data company, has unveiled significant organizational changes and a new collaborative effort aimed at advancing cardiovascular research. These developments mark a pivotal moment for the company as it continues to expand its influence in the digital health sector.

Leadership Transition: Leslie Oley Wilberforce Elevated to CEO

Evidation has announced the promotion of Leslie Oley Wilberforce to the position of Chief Executive Officer. Wilberforce, who previously served as the company's President and Chief Operating Officer, will succeed co-founder Christine Lemke in this role. Lemke will transition to an advisory position and maintain her seat on the board of directors.

During her tenure as COO, Wilberforce played a crucial role in establishing Evidation's research platform as an enterprise product. Her leadership was instrumental in forging key partnerships, including collaborations with the Michael J. Fox Foundation to explore digital biomarkers for Parkinson's disease and with the Our Future Health Initiative at the U.K. National Health Service.

Christine Lemke praised Wilberforce's appointment, stating, "Leslie is a driven leader whose operational prowess and people-first leadership approach has made her an indispensable force behind Evidation's success and the right leader for this moment." Lemke expressed confidence in Wilberforce's ability to propel Evidation to greater impact in the coming years.

Strategic Partnership with American Heart Association

Concurrent with the leadership announcement, Evidation revealed a new partnership with the American Heart Association (AHA) to support the Research Goes Red program. This initiative aims to increase female participation in cardiovascular studies, addressing a critical need in medical research.

The collaboration underscores Evidation's commitment to leveraging its digital health platform for targeted research efforts. By focusing on women's cardiovascular health, the partnership seeks to enhance understanding of how heart diseases uniquely affect this demographic.

Evidation's Continued Growth and Industry Position

Evidation's recent moves reflect its ongoing strategy to strengthen its position in the digital health and real-world data sectors. The company, a former Fierce Medtech Fierce 15 winner, has consistently expanded its reach through strategic partnerships and platform enhancements.

In a related development, Evidation recently appointed Phil Johnson as Chief Commercial Officer. Johnson, formerly a VP at Tempus and a healthcare leader at Amazon Web Services, is expected to support Evidation's push toward more partnerships and commercial growth.

These latest announcements underscore Evidation's trajectory as a key player in bridging the gap between digital health technologies and actionable medical research, positioning the company for continued innovation and expansion in the evolving healthcare landscape.